Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis
NCT06460506Phase 3Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 100 weeks. Started Nov 2024; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT06460506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06460506.